Wohn-Jenn Leu
Overview
Explore the profile of Wohn-Jenn Leu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsu J, Leu W, Hsu L, Hsieh C, Guh J
Oncol Lett
. 2024 Mar;
27(4):170.
PMID: 38455663
Lung cancer is the leading cause of cancer-related death worldwide, and ~85% of lung cancers are non-small cell lung cancer (NSCLC), which has a low 5-year overall survival rate and...
2.
Du C, Leu W, Jiang Y, Chan S, Chen I, Chang H, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2024 Mar;
397(9):6533-6550.
PMID: 38451282
The treatment of non-small cell lung cancer (NSCLC) is known as a significant level of unmet medical need in spite of the progress in targeted therapy and personalized therapy. Overexpression...
3.
Ye P, Leu W, Yeh T, Hsu Y, Lin Y, Wei Z, et al.
Prostate
. 2024 Feb;
84(6):605-619.
PMID: 38375594
Background: Metastatic castration-resistant prostate cancer (CRPC), the most refractory prostate cancer, inevitably progresses and becomes unresponsive to hormone therapy, revealing a pressing unmet need for this disease. Novel agents targeting...
4.
Chiang Y, Leu W, Chen Y, Ye P, Hsu Y, Hsiao Y, et al.
Prostate
. 2023 Aug;
83(16):1549-1563.
PMID: 37583103
Background: Castration-resistant prostate cancer (CRPC) is refractory to hormone treatment and the therapeutic options are continuously advancing. This study aims to discover the anti-CRPC effects and underlying mechanisms of small-molecule...
5.
Weng H, Sung C, Hsu J, Leu W, Guh J, Kung F, et al.
Front Pharmacol
. 2022 Jun;
13:879748.
PMID: 35662690
Breast cancer is the most prevalent cancer and the second leading cause of cancer death in women. Cisplatin is a commonly used chemotherapeutic drug for breast cancer treatment. Owing to...
6.
Leu W, Chang H, Chen I, Guh J, Chan S
Int J Mol Sci
. 2021 Oct;
22(20).
PMID: 34681898
Acute myeloid leukemia (AML) is one of the most common forms of leukemia. Despite advances in the management of such malignancies and the progress of novel therapies, unmet medical needs...
7.
Hsu J, Leu W, Zhong N, Guh J
Molecules
. 2021 Oct;
26(19).
PMID: 34641511
Non-small cell lung cancer (NSCLC), an aggressive subtype of pulmonary carcinomas with high mortality, accounts for 85% of all lung cancers. Drug resistance and high recurrence rates impede the chemotherapeutic...
8.
Huang T, Deng Y, Hsu J, Leu W, Marchesi E, Capobianco M, et al.
Front Pharmacol
. 2020 Dec;
11:599067.
PMID: 33343369
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy in adults and accounts for 85-90% of all primary liver cancer. Based on the estimation by the International Agency for...
9.
Leu W, Chu J, Hsu J, Du C, Jiang Y, Hsu L, et al.
Molecules
. 2020 Dec;
25(24).
PMID: 33339319
Chalcones are responsible for biological activity throughout fruits, vegetables, and medicinal plants in preventing and treating a variety of inflammation-related diseases. However, their structure-activity relationship (SAR) in inhibiting inflammasome activation...
10.
Hsu J, Leu W, Hsu L, Ho C, Liu S, Guh J
Front Oncol
. 2020 Aug;
10:1274.
PMID: 32850387
Combination therapies that display cancer-killing activities through either coexistent targeting of several cellular factors or more efficient suppression of a specific pathway are generally used in cancer treatment. Sildenafil, a...